Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pfizer and BioNTech forge new COVID-19 vaccine deal with U.S. government

By Brian Buntz | June 29, 2022

Pfizer-BioNTechPfizer Inc. (NYSE:PFE) and its partner BioNTech SE (Nasdaq:BNTX) profited handsomely from COVID-19 vaccine sales in 2021. The firms raked in more than $59 billion in combined sales of the Comirnaty vaccine. 

The two companies have now announced a new vaccine supply agreement with the U.S. government worth $3.2 billion. Under the terms of the agreement, the government will receive 105 million additional doses of the vaccine at the 30 µg, 10 µg and 3 µg dose levels. 

The deal could include an omicron-adapted COVID-19 vaccine, assuming FDA authorizes an updated booster. 

Yesterday, FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted to back the use of omicron-containing boosters.

Pfizer announced that it could begin shipping doses for the deal as soon as the late summer and continue into the fourth quarter of 2022. 

The U.S. government also has the option to buy up to 195 million additional doses for a total of 300 million doses.

The U.S. had a population of 330 million in 2020.  

“This agreement will provide additional doses for U.S. residents and help cope with the next COVID-19 wave,” said Sean Marett, chief business and chief commercial officer of BioNTech. “Pending regulatory authorization, it will also include an omicron-adapted vaccine, which we believe is important to address the rapidly spreading omicron variant.”

Pfizer and BioNTech recently released data related to monovalent and bivalent vaccines based on the omicron BA.1 variant. 

When given as a fourth dose, the monovalent vaccine candidate resulted in a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg doses. 

U.S. regulators may prefer a vaccine based on the BA.4/BA.5 omicron subvariant or a future variant. 

PFE shares ticked up 0.51% to $50.94. BNTX shares were up 1.54% to $141.98, 


Filed Under: Drug Discovery and Development, Infectious Disease
Tagged With: BioNTech, COVID-19 vaccine, FDA, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Axcella
Axcella touts positive results from Phase 2a long COVID study
monkeypox
3 critical monkeypox vaccine questions 
Moderna in the Drug Discovery & Development Pharma 50
Moderna inks deal with US for up to 300M omicron boosters
Vaccine
FDA greenlights 786,000 additional monkeypox vaccine doses

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50